Anti-metabolic syndrome effects of adenosine ingestion in stroke-prone spontaneously hypertensive rats fed a high-fat diet.
We have demonstrated previously that both acute and chronic oral administration of adenosine have novel functions such as anti-hypertensive effects and improved hyperlipidaemia in stroke-prone spontaneously hypertensive rats (SHRSP) fed a normal diet. The purpose of the present study was to investigate the effect of adenosine administration on metabolic syndrome-related parameters in SHRSP fed a high-fat diet. Six-week-old rats were divided into three groups, and were administered either water (control) or adenosine (10 or 100 mg/l) for 8 weeks. During this period, the rats had free access to a high-fat diet based on AIN-93M. The results showed that hypertension, plasma lipid, NO, insulin, glucose and urinary 8-hydroxy-2'-deoxyguanosine levels improved significantly in both adenosine groups. The mRNA expression levels of genes involved in anti-oxidative activity and adenosine receptors were also altered in the adenosine groups. Administration of adenosine also increased plasma adiponectin levels, accompanied by upregulation of mRNA expression level of adiponectin and adiponectin receptor 1 in perirenal fat and adiponectin receptor 2 in the liver. In conclusion, oral administration of adenosine is effective for improving metabolic syndrome-related parameters in SHRSP, and accordingly it may prevent the progression of the metabolic syndrome.
Ardiansyah
Laboratory of Nutrition, Graduate School of Agricultural Science, Tohoku University, 1-1 Tsutsumidori-Amamiyamachi, Aoba-ku, Sendai 981-8555, Japan. ardy@biochem.tohoku.ac.jp
Shirakawa
Hitoshi
H
Sugita
Yumi
Y
Koseki
Takuya
T
Komai
Michio
M
D000080242:8-Hydroxy-2'-Deoxyguanosine; D000241:Adenosine / Q000494:pharmacology* / Q000627:therapeutic use; D052242:Adiponectin / Q000097:blood; D000273:Adipose Tissue / Q000378:metabolism; D000818:Animals; D000975:Antioxidants / Q000378:metabolism / Q000494:pharmacology; D001786:Blood Glucose / Q000378:metabolism; D002317:Cardiovascular Agents / Q000494:pharmacology* / Q000627:therapeutic use; D003849:Deoxyguanosine / Q000031:analogs & derivatives / Q000652:urine; D004041:Dietary Fats / Q000008:administration & dosage*; D004798:Enzymes / Q000235:genetics / Q000378:metabolism*; D015870:Gene Expression; D005786:Gene Expression Regulation; D006973:Hypertension / Q000188:drug therapy / Q000378:metabolism*; D007328:Insulin / Q000097:blood; D007668:Kidney / Q000378:metabolism; D008055:Lipids / Q000097:blood; D008099:Liver / Q000378:metabolism; D008297:Male; D024821:Metabolic Syndrome / Q000188:drug therapy / Q000378:metabolism*; D009569:Nitric Oxide / Q000097:blood; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D011918:Rats, Inbred SHR; D054419:Receptors, Adiponectin / Q000235:genetics / Q000378:metabolism; D020521:Stroke
D052242:Adiponectin; D000975:Antioxidants; D001786:Blood Glucose; D002317:Cardiovascular Agents; D004041:Dietary Fats; D004798:Enzymes; D007328:Insulin; D008055:Lipids; D012333:RNA, Messenger; D054419:Receptors, Adiponectin; D009569:Nitric Oxide; D000080242:8-Hydroxy-2'-Deoxyguanosine; D003849:Deoxyguanosine; D000241:Adenosine